司美格鲁肽在肥胖人群中的应用

Application of semaglutide in obese population

司美格鲁肽作为体重管理的胰高血糖素样肽1受体激动剂,可延缓胃排空,增加饱腹感,减少能量摄入,还可以优化肌肉内脂肪,激活脂肪细胞褐变,增加能量消耗,进而降低机体体重。司美格鲁肽周制剂治疗成年超重和肥胖,能减轻体重、减少腰围,同时还能改善血脂、血糖及血压等代谢相关指标,间接降低心血管疾病的发生风险,且安全性好。司美格鲁肽已被美国食品和药物管理局批准用于治疗青少年肥胖,应用前景广阔。

As a glucagon-like peptide1 receptor agonist for weight management,semaglutide can delay gastric emptying,increase satiety,reduce energy intake,optimize intra-muscle fat,activate adipocyte browning,increase energy consumption,and thus reduce body weight.In the treatment of overweight and obesity in adults,semaglutide weekly preparation can reduce the weight and waist circumference,and at the same time improve lipid,blood sugar,blood pressure and other related metabolic indicators,indirectly reducing the risk of cardiovascular diseases,with good safety.Semaglutide has been approved by U.S.FDA for the treatment of obesity in adolescents,which has a broad application prospect.